Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Pfizer
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01353963
First received: May 12, 2011
Last updated: September 10, 2014
Last verified: September 2014
  Purpose

This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.


Condition Intervention
Major Depressive Disorder
Vasomotor Symptoms
Drug: desvenlafaxine succinate

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: An Open Label, Non-Interventional Study of the Safety of Desvenlafaxine Succinate (Pristiq) in the Treatment of Major Depressive Disorder (MDD) and Vasomotor Symptoms (VMS) Associated With Menopause in Filipino Adult Patients: a Post Marketing Surveillance Study

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Safety assessments as measured by evaluating any reported adverse events, scheduled physical examinations and vital signs assessments. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 3000
Study Start Date: March 2012
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 Drug: desvenlafaxine succinate
50 mg tablet once daily
Other Name: Pristiq

Detailed Description:

post marketing surveillance none

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to menopause prescribed with desvenlafaxine succinate

Criteria

Inclusion Criteria:

Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to menopause prescribed with desvenlafaxine succinate

Exclusion Criteria:

Hypersensitivity to desvenlafaxine succinate

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01353963

Contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021

Locations
Philippines
Private Clinic Recruiting
Las Pinas, Philippines
Private Clinic Recruiting
Manila, Philippines
Private Clinic Recruiting
Pasay City, Philippines
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01353963     History of Changes
Other Study ID Numbers: B2061038
Study First Received: May 12, 2011
Last Updated: September 10, 2014
Health Authority: Philippines: Food and Drug Administration (FDA)

Additional relevant MeSH terms:
Depressive Disorder, Major
Depressive Disorder
Depression
Disease
Mood Disorders
Mental Disorders
Behavioral Symptoms
Pathologic Processes
O-desmethylvenlafaxine
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 22, 2014